Alternatives to Apretude If You Can't Fill Your Prescription

Apretude is a landmark HIV prevention tool — but it's not the only one. If you can't access Apretude because of insurance hurdles, lack of a nearby provider, or any other barrier, there are other FDA-approved PrEP options that can protect you while you work out access. In this guide, we'll walk through each alternative and help you figure out which might work best for your situation.

First: Don't Go Unprotected While You Wait

If there's a gap in your access to Apretude — whether you're waiting on insurance approval, searching for a provider, or moving to a new city — it's critical to use an alternative PrEP regimen in the meantime. Daily oral PrEP reaches full protection after about 7 days for anal sex and 21 days for vaginal sex.

Alternative 1: Generic Truvada (Emtricitabine/Tenofovir Disoproxil Fumarate)

Generic Truvada (emtricitabine/tenofovir disoproxil fumarate, also written TDF/FTC) is the most widely available and affordable oral PrEP option. It became generic in 2020, making it accessible at most pharmacies for $30-$100 per month — a fraction of brand-name costs.

It's taken once daily and is approved for all populations, including cisgender women at risk from receptive vaginal sex, cisgender men who have sex with men, transgender individuals, and people at risk through injection drug use. When taken consistently, it reduces HIV risk by up to 99%.

The main considerations: it requires daily adherence (easy to miss doses), and there are modest risks of kidney function decline and bone density loss with long-term use — though these are generally mild and reversible.

Best for: Anyone who needs the most affordable option, anyone who prefers at-home medication, people at risk through receptive vaginal sex or injection drug use.

Alternative 2: Descovy (Emtricitabine/Tenofovir Alafenamide)

Descovy (FTC/TAF) is also a once-daily oral PrEP pill. It uses a newer formulation of tenofovir (TAF) that is associated with lower rates of kidney toxicity and bone density loss compared to Truvada. For people with kidney concerns or who are at higher risk for bone loss, Descovy may be the better oral option.

Important limitation: Descovy is NOT approved for individuals at risk from receptive vaginal sex. It's approved for cisgender men who have sex with men and for transgender individuals. Also, there is no FDA-approved US generic as of 2026, making it significantly more expensive — brand-name Descovy runs well over $2,000 per month at list price, though insurance and patient assistance programs can reduce this substantially.

Best for: Cisgender men and transgender individuals at risk from anal sex who have kidney or bone health concerns and have adequate insurance coverage.

Alternative 3: Yeztugo (Lenacapavir) — Every 6 Months

Yeztugo (lenacapavir) is the newest injectable PrEP option, FDA approved in June 2025. It is administered just twice a year — every six months — making it the least frequent dosing option currently available. Clinical trials showed approximately 99% efficacy, with some studies reporting zero HIV infections among participants.

Like Apretude, Yeztugo is administered by a healthcare provider. Because it's newer, provider availability and insurance coverage are still expanding — you may encounter similar access challenges as with Apretude. Long-term real-world data is also still emerging since it's been available less than a year.

Best for: People who prefer even less frequent dosing than Apretude, and have access to a provider offering Yeztugo.

Side-by-Side Comparison of PrEP Options

Here's how the four FDA-approved PrEP options compare on key dimensions:

Apretude (cabotegravir injection): Every 2 months, clinic-administered, 69-90% more effective than Truvada in trials, no daily pill burden, $0 with insurance for most, approved for all sexes

Generic Truvada (TDF/FTC): Daily pill, pharmacy dispensed, ~$30-100/month generic, approved for all sexes including vaginal sex, most widely available

Descovy (FTC/TAF): Daily pill, pharmacy dispensed, better kidney/bone profile, NOT approved for receptive vaginal sex, brand-only in US

Yeztugo (lenacapavir): Every 6 months injection, clinic-administered, newest option, ~99% effective, coverage still expanding

Talk to Your Provider Before Switching

The best PrEP option is the one you can consistently access and adhere to. Talk openly with your provider about your lifestyle, insurance, and preferences. If daily adherence is a challenge, an injectable option may ultimately be better even if it takes more time to access upfront.

If you're still trying to access Apretude specifically, read our guide on how to find Apretude near you. And if you need help locating any of these medications, medfinder can help.